New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
ETF What's Up
Don’t Miss a Move in the ETF Market
Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.
BIGT ETF · L&G Pharma Breakthrough UCITS ETF
The BIGT Exchange Traded Fund (ETF) is provided by L&G. It is built to track an index: Solactive Pharma Breakthrough Value Index. The BIGT ETF provides physical exposure, so by buying it you actually own parts of all the 36 underlying holdings. The dividend policy is capitalization.
Last update Yesterday at 8:00 AM UTC
LIVE
CLOSED
This fund is part ofWorld Blended Cap1M perf.-4.08%
Last price
£977.40
1M perf.
-5.06%
1M flows
N/A
AuM
€17M
E/R
0.49%
Rating
ESG Consensus®
BIGT
£977.40
Performance & flows
Segment for quartile rank
December 12, 2025 → March 12, 2026
Create a free account to view the flows graph
BIGT
$13.08
-4.67%
World Blended Cap
+1.00%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -5.06%  | -4.67% | +21.62%  | +17.65% | +4.40% | -5.90% | -4.21% | -4.21% | |
| Flows |
Key fund info
Segment for quartile rank
Main characteristics
More details
NAV
3/12/2026
$13.08
1D NAV change
-2.78%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
36
Inception date
1/23/2018
Jurisdiction
Ireland
Distribution
Finland
United Kingdom
Ireland
Italy
Luxembourg
Legal structure
Open-end Investment Company
Base currency
USD
Classification
Product type
Benchmark
Solactive Pharma Breakthrough Value Index
Asset class
Factors
N/A
Investment strategy
The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs
XHE
1M perf.
-4.50%
E/R
0.35%
AAKG
1M perf.
-5.74%
E/R
0.75%
HMMJ
1M perf.
+2.64%
E/R
1%
476070
1M perf.
-6.38%
E/R
0.45%
GNOG
1M perf.
-4.19%
E/R
0.5%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -4.67% | +21.62%  | +17.65% | +4.40% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
1
2
3
4
5
6
7
PRIIPS
1
2
3
4
5
6
7
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
63.76%
Japan
11.21%
Netherlands
3.38%
Sweden
3.23%
Switzerland
2.99%
Denmark
2.93%
France
2.91%
United Kingdom
2.89%
Republic of Korea
2.74%
Other
3.92%
Sectors
Health Care
87.57%
Materials
2.74%
Unavailable
9.69%
Diversification
Total weight of top 15 holdings out of 36
Top 15 holdings
Data as of January 31, 2026
NIPPON SHINYAKU
BRIDGEBIO PHARMA
TRAVERE THERAPEUTICS INC
XENCOR INC/D
MIRUM PHARMACEUTICALS INC
PHARMING GROUP
IONIS PHARMACEUTICALS INC
PTC THERAPEUTI/D
Create a free account to view top holdings
SWEDISH ORPHAN BIOVITRUM
BIOGEN INC
CHUGAI PHARMACEUTICAL
US5907174016
CATALYST PHARMACEUTICALS INC
BASILEA PHARMACEUTICA
VERTEX PHARMACEUTICALS
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
Yes
SDG
ESG Consensus® by Conser
Data as of December 31, 2025
MethodologyOur partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about BIGT ETF's sustainability, based on their methodology.
ESG Consensus®
ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.
BIGT’s has a Final Sustainability Grade of either B+, B, or B-.
A+
A
A-
B+
B
B-
C+
C
C-
D
This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight EnterpriseHoldings review
82.19% of holdings have positive scoring
17.85% of holdings have negative scoring
8.74%
55.16%
18.29%
5.99%
11.85%
Consensus levels
Strong
Medium
Weak
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseReplication
Trackinsight replication rating:
Replication quality
Calculated over 12m, as of February 27, 2026
Tracking error
Tracking difference
Replication information
Index
Solactive Pharma Breakthrough Value NTR Index - USD
Index ticker
SOLBIOT Index
Index dividend policy
NTR
Replication method
Replication model
Built for professionals: access exclusive replication metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
L&G
L&G ID Card
Number of funds
72
Total AuM
€20.92B
Expense ratio range
0.05% - 0.8%
Average expense ratio
0.3324%
Top 5 funds by L&G
| AuM | ||
|---|---|---|
ISPY | L&G Cyber Security UCITS ETF | €2.22B |
AIAG | L&G Artificial Intelligence UCITS ETF | €1.22B |
LGUS | L&G US Equity UCITS ETF | €1.05B |
ENCO | L&G Multi-Strategy Enhanced Commodities UCITS ETF | €1.02B |
ECGH | L&G Multi-Strategy Enhanced Commodities UCITS ETF | €1.01B |
Frequently asked questions about BIGT
What does L&G Pharma Breakthrough UCITS ETF, BIGT, invest in?
BIGT is a Passive ETF. This ETF provides exposure to Other Equities.
Which benchmark or index does BIGT replicate?
BIGT tracks the Solactive Pharma Breakthrough Value NTR Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of BIGT?
BIGT carries a total expense ratio (TER) of 0.49%, indicating the annual cost for holding the fund.
When was BIGT launched?
BIGT was introduced to the market on January 23, 2018. It trades on Finland, among other exchanges
Who is the ETF issuer of BIGT?
L&G Pharma Breakthrough UCITS ETF, BIGT, is provided by L&G. Learn more about L&G here.
What is the current assets under management (AUM) of BIGT?
BIGT oversees €17M in assets as of March 12, 2026.
How has BIGT performed lately?
Based on data from March 12, 2026, BIGT returned -5.06% over the past month, -4.67% over the last three months and -4.21% year-to-date.
What are the latest inflows or outflows for BIGT?
As of March 12, 2026, BIGT recorded net flows of +€584K year-to-date.
Does BIGT distribute dividends?
BIGT follows a capitalizing, meaning it reinvests income within the fund.
What are the main country or region exposures of BIGT?
As of January 31, 2026, BIGT has significant geographic allocations in USA, Japan and Netherlands.
In which sector or theme does BIGT invest in?
As of January 31, 2026, BIGT focuses largely on Health Care and Materials.
How many securities does BIGT hold and how diversified is it?
As of January 31, 2026, BIGT holds 36 positions in its portfolio, with 49.54% of assets concentrated in its top 15 holdings.
What are the main positions in BIGT?
As of January 31, 2026, BIGT top three holdings include NIPPON SHINYAKU, BRIDGEBIO PHARMA and TRAVERE THERAPEUTICS INC.
What is the base currency of BIGT?
The base currency of BIGT is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
